9MI0 image
Deposition Date 2024-12-12
Release Date 2025-05-21
Last Version Date 2025-05-28
Entry Detail
PDB ID:
9MI0
Keywords:
Title:
61-12A01 Fab in complex with HIV-1 GT1.1 v4.1 SOSIP Env trimer and RM20A3 Fab
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.80 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:GT1.1 v4.1 SOSIP gp120
Chain IDs:E (auth: A), K (auth: C), Q (auth: E)
Chain Length:509
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:Envelope glycoprotein gp160
Chain IDs:F (auth: B), L (auth: D), R (auth: F)
Chain Length:153
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:RM20A3 heavy chain Fv
Chain IDs:C (auth: G), I (auth: J), O
Chain Length:125
Number of Molecules:3
Biological Source:Macaca mulatta
Polymer Type:polypeptide(L)
Molecule:61_12A01 heavy chain Fv
Chain IDs:A (auth: H), G (auth: K), M (auth: P)
Chain Length:123
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:RM20A3 light chain Fv
Chain IDs:D (auth: I), J (auth: M), P (auth: Q)
Chain Length:128
Number of Molecules:3
Biological Source:Macaca mulatta
Polymer Type:polypeptide(L)
Molecule:61_12A01 kappa chain Fv
Chain IDs:B (auth: L), H (auth: N), N (auth: R)
Chain Length:104
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01B, induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, that target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures